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Background:  Although  percutaneous  coronary  intervention  (PCI)  in patients  with  diabetes  mellitus  (DM)
is associated  with  worse  clinical  outcomes,  the efﬁcacy  of  drug-eluting  stents  (DES)  in Japanese  patients
and differences  in effectiveness  between  different  DES  types  remain  unknown.
Methods and  subjects:  Five-hundred  and  sixty-two  consecutive  patients  (183  with  DM,  379  without  DM)
with  676  lesions  were  treated  with  sirolimus-eluting  stents  (SES,  n = 531;  160  DM  group,  371 non-DM
group)  or  paclitaxel-eluting  stents  (PES,  n =  145;  64  and  81,  respectively).  We  assessed  the initial  and
8-month  follow-up  clinical  and  angiographic  outcomes.
Results:  There  were  no signiﬁcant  differences  in  clinical  and  lesion  characteristics,  although  the  pre-
minimum  luminal  diameter  was  smaller  in the DM  group  (p =  0.016).  The  risk  of  major  adverse  cardiac
events (MACE),  deﬁned  as  cardiac  death,  non-fatal  myocardial  infarction,  congestive  heart  failure,  or
recurrent  angina  pectoris,  was  higher  in  the  DM  group  compared  with  the  non-DM  group  (17.4%  vs  9.5%,
p = 0.007).  Among  diabetic  patients,  although  SES  reduced  late  loss by  0.45  mm  (p  < 0.001)  and  the  binary
restenosis  rate  by  66.4%  (7.4%  vs  22.0%,  p <  0.001)  compared  with  PES  at 8  months,  it  did  not  reduce  target
lesion  revascularization  or MACE,  as in  the  non-DM  group.
Conclusions:  Diabetic  patients  have  worse  mid-term  prognosis  than  non-diabetic  patients  undergoing
PCI  with  DES.  Although  the  superiority  of SES  in  terms  of late  loss  or restenosis  may  not  play  a  clinically
meaningful  role  in the treatment  of  diabetic  patients,  this  phenomenon  was  independent  of  the  presence
of  diabetes.
2  Jap© 201
ntroduction
Percutaneous coronary intervention (PCI) in patients with dia-
etes mellitus (DM) is associated with an increased risk of adverse
linical outcomes compared with those without DM [1–3]. Recent
ata have demonstrated that drug-eluting stents (DES) reduce the
ncidence of restenosis and the need for repeated revascularization
ompared with bare-metal stents in patients with DM [4,5]. Fur-
hermore, sirolimus-eluting stents [6] (SES) and paclitaxel-eluting
tents [7] (PES) dramatically reduce angiographic measures and
linical events compared with bare metal stents in patients with
nd without DM.  However, the relative efﬁcacy of SES and PES in
M patients remains unclear.
For example, although a recent systematic review of 5 random-
zed trials reported superior outcomes regarding late loss, binary
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restenosis, and target lesion revascularization (TLR) with SES in DM
patients [8],  in 8 registries reporting outcomes with both stents, the
likelihood of target vessel failure and major adverse cardiac events
(MACE) was  not higher than those of PES [9].  Therefore, the efﬁ-
cacy and differences between the 2 types of stents in patients with
DM have been controversial. Furthermore, it is not known whether
there are differences in the effectiveness of the 2 stents in Japanese
patients, as there has been no randomized trial or registry in Japan.
Therefore, we evaluated the impact of DM on initial and mid-
term clinical and angiographic outcomes after PCI with SES and PES
and clariﬁed the relative difference in efﬁcacy between SES and PES
in actual Japanese patients.
Methods
Patient population and interventionOur study included 562 consecutive patients (183 with DM and
379 without DM)  with 676 lesions who had received DES from
August 2004 to December 2009. DES consisted of 531 SES (160 DM
vier Ltd. All rights reserved.
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Table 1
Baseline characteristics.
DM SES PES Non DM SES PES p value DM vs non DM SES vs PES
n 129 54 308 71
Age 67.3 ± 9.0 68.8 ± 9.3 69.3 ± 10.7 71.5 ± 10.7 0.031 0.116
Male,  n (%) 93 (72.1) 38 (70.4) 217 (70.5) 54 (76.1) 0.984 0.561
HbA1c  (%) 7.61 ± 1.70 7.30 ± 1.41 – – – 0.221
Risk  factors, n (%)
Diabetes mellitus 129 54 0 0 – 0.004
Smoking 36 (27.9) 13 (24.0) 97 (31.5) 16 (22.5) 0.456 0.115
Obesity  39 (30.2) 12 (22.2) 88 (28.6) 21 (29.6) 0.826 0.561
Family  history 9 (7.0) 5 (9.3) 26 (8.4) 6 (8.5) 0.748 0.776
Hypertension 80 (62.0) 34 (63.0) 135 (43.8) 34 (47.9) <0.001 0.305
Dyslipidemia 78 (60.5) 33 (61.1) 101 (32.8) 25 (35.2) <0.001 0.278
Previous MI  69 (53.5) 26 (48.1) 96 (31.2) 17 (23.9) <0.001 0.395
Previous PCI 72 (55.8) 28 (51.9) 106 (34.4) 22 (31.0) <0.001 0.989
LVEF  (%) 57.8 ± 17.1 59.6 ± 14.6 60.1 ± 18.8 57.2 ± 15.6 0.737 0.623
DM,  diabetes mellitus; SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; HBA1c, glycated hemoglobin; MI,  myocardial infarction; PCI, percutaneous coronary
intervention; LVEF, left ventricular ejection fraction.
Table 2
Lesion characteristics.
DM SES PES Non DM SES PES p value DM vs non DM SES vs PES
Total number of lesions 160 64 371 81
Treated vessel, n (%) 0.783 0.687
Left  main 2 (1.3) 0 3 (0.8) 0
Left anterior descending 79 (49.4) 31 (48.4) 181 (48.8) 40 (49.4)
Left  circumﬂex 30 (18.8) 11 (17.2) 66 (17.8) 15 (18.5)
Right 47 (29.4) 21 (32.8) 118 (31.8) 26 (32.1)
Saphenous bypass graft 2 (1.3) 1 (1.6) 3 (0.8) 0
Lesion type (ACC/AHA), n (%) 0.725 0.615
A 8(5.0)  3 (4.7) 27 (7.3) 5 (6.2)
B1  30 (18.8) 14 (21.9) 66 (17.8) 16 (19.8)
B2/C 122 (76.2) 47 (73.4) 278 (74.9) 60 (74.0)
D  ACC/A
g
n
w
e
2
t
〈
b
t
a
t
i
o
t
c
t
T
A
DM,  diabetes mellitus; SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents;
roup and 371 non-DM group) and 145 PES (64 DM group and 81
on-DM group) (Tables 1 and 2). From August 2004 to May 2007,
e deployed SES in all patients. After that, although we selected
ach DES almost equally (numbers of lesions were 58 vs 48 in
007, 65 vs 66 in 2008, 29 vs 31 in 2009, 〈SES vs PES〉, respec-
ively), PES 〈54/125(43.2%)〉 was used more frequently than SES
129/437(29.5%)〉 in diabetic patients (Table 1). Wherever possi-
le, we implanted the same stent if DES had been used before in
he patient. Patients were assigned to treatment with SES or PES
fter discussion with the ﬁrst operator and another 1 or 2 interven-
ional cardiologists. There were 8 overlap cases (SES was  deployed
n previous PCI) in PES with DM and 10 overlap cases in PES with-
ut DM. Although we calculated all results excluding these cases,
he results were the same. Therefore, we included these overlap
ases. The analyses were based on the type of stent implanted at
he ﬁrst recorded procedure. Patients who received at least one
able 3
ngiographic characteristics and initial results.
DM SES PES Non DM SES PES A
Number of stents 1.25 ± 0.49 1.12 ± 0.33 1.26 ± 0.51 1.19 ± 0.43 
Stent size (mm) 2.93 ± 0.41 2.82 ± 0.35 2.98 ± 0.37 2.83 ± 0.36 
Stent length (mm)  25.8 ± 12.6 20.4 ± 7.4 26.3 ± 13.5 21.5 ± 12.3 
Lesion length (mm) 14.7 ± 11.7 10.3 ± 5.5 14.4 ± 11.7 9.9 ± 9.0 
Pre  RD (mm) 2.18 ± 0.59 2.32 ± 0.63 2.23 ± 0.51 2.33 ± 0.84 
Pre  MLD (mm) 0.67 ± 0.38 0.47 ± 0.27 0.73 ± 0.40 0.56 ± 0.30 
Post  RD (mm) 2.69 ± 0.46 2.76 ± 0.48 2.66 ± 0.45 2.71 ± 0.40 
Post  MLD  (mm) 2.27 ± 0.45 2.34 ± 0.57 2.28 ± 0.46 2.38 ± 0.34 
M,  diabetes mellitus; SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; RD, reHA, American College of Cardiology/American Heart Association.
DES were included in the analysis, regardless of whether they had
received another type of stent at any time. The same assigned stent
had to be implanted in all lesions in patients who  required sten-
ting in multiple lesions simultaneously; the use of more than one
stent per lesion was also allowed. Eligible patients had a history of
stable or unstable angina pectoris or silent ischemia and presented
with at least one lesion with a diameter stenosis of more than 75%
in a vessel with a reference vessel diameter or more than 50% in
the presence of ischemic signs with exercise electrocardiography
or scintigraphy (Tl) between 2.25 and 4.50 mm suitable for stent
implantation. The study excluded patients with acute myocardial
infarction diagnosed on the basis of chest pain of more than 30 min
duration, ST segment elevation of more than 2 mm in two contigu-
ous electrocardiographic leads and more than a threefold increase
in serum creatine kinase activity. PCI was performed according to
current standard procedural guidelines. A successful procedure was
ll DM All non DM p value All SES All PES p value
1.22 ± 0.46 1.25 ± 0.50 0.391 1.26 ± 0.50 1.16 ± 0.39 0.031
2.85 ± 0.44 2.96 ± 0.39 0.358 2.95 ± 0.38 2.83 ± 0.35 0.182
25.5 ± 12.4 26.1 ± 13.6 0.784 26.0 ± 13.3 21.2 ± 10.5 <0.001
14.8 ± 11.1 14.2 ± 10.6 0.669 14.3 ± 11.7 10.2 ± 7.7 <0.001
2.22 ± 0.62 2.25 ± 0.51 0.856 2.21 ± 0.53 2.32 ± 0.75 0.078
0.58 ± 0.34 0.68 ± 0.37 0.016 0.71 ± 0.39 0.52 ± 0.29 <0.001
2.72 ± 0.45 2.69 ± 0.44 0.482 2.67 ± 0.45 2.73 ± 0.44 0.247
2.30 ± 0.49 2.31 ± 0.44 0.848 2.27 ± 0.45 2.36 ± 0.46 0.065
ference diameter; MLD, minimum luminal diameter.
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eﬁned as less than 25% residual stenosis following the procedure.
he study protocol was approved by the ethics committee at our
nstitution. All patients gave written informed consent.
djunct drug therapy
Before or at the time of the procedure, patients received at
east 100 mg  of aspirin and 100 mg  of ticlopidine twice a day (from
ugust 2004 to May  2006) or 75 mg  of clopidogrel (loading dose
f 300 mg)  (from June 2006). After the procedure, all patients were
dvised to continue taking aspirin lifelong and clopidogrel was  pre-
cribed for at least 12 months, irrespective of stent type.
uantitative coronary angiography and follow-up protocol
We  assessed the initial and 8-month follow-up clinical and
ngiographic outcomes retrospectively. Baseline, postprocedural,
nd follow-up coronary angiograms were digitally recorded and
ssessed by an interventional cardiologist or experienced person-
el unaware of the type of stent implanted. The complexity of
he lesions was deﬁned according to the modiﬁed grading system
f the American College of Cardiology–American Heart Associa-
ion [10]. All measurements were performed on cineangiograms
ecorded after the intracoronary administration of nitroglycerin. A
ontrast-ﬁlled nontapered catheter tip of 4F or 5F was used for cal-
bration. Quantitative coronary angiography was performed from 2
rthogonal projections that well delineated the coronary artery of
nterest, without overlapping of side branches and with little fore-
hortening, using the Philips quantitative coronary analysis system
Philips Medical, Best, The Netherlands) and was  assessed by an
nterventional cardiologist or experienced personnel unaware of
he type of stent implanted. Quantitative analysis was used to
valuate the stented area and the area that included the stented
egment, as well as the 5 mm margins proximal and distal to the
tent (deﬁned as in-stent).
All patients were asked to return for coronary angiography at
ight months after the procedure, or earlier if angina symptoms
ccurred.
eﬁnitions
DM was diagnosed in all patients receiving active treatment
ith an oral hypoglycemic agent or insulin; for patients with a
iagnosis of DM who were receiving dietary therapy alone, enroll-
ent in the present study required documentation of an abnormal
lood glucose level (126 mg/dl) after an overnight fast, an abnor-
al  glycosylated hemoglobin (HbA1c) test (6.5%), or an abnormal
lucose-tolerance test (2 h  200 mg/dl) [11]. Data on other cardio-
ascular risk factors such as hypertension, dyslipidemia, smoking,
nd family history were reported by the patients themselves or
aken from laboratory analysis.
We evaluated late luminal loss on follow-up angiography, angi-
graphic binary restenosis (deﬁned as in-stent restenosis of at least
0% on follow-up angiography), and TLR at 8 months. TLR was con-
idered to be driven by ischemia if the stenosis of the target lesion
as more than 50% on the basis of quantitative coronary angiog-
aphy in the presence of ischemic signs or symptoms, or if there
as a stenosis of more than 75% even in the absence of ischemic
igns or symptoms. Furthermore, we assessed MACE, deﬁned as a
omposite of cardiac death, nonfatal myocardial infarction, recur-
ent angina pectoris, or admission due to congestive heart failure.
ongestive heart failure was deﬁned clinically as the presence of a
hird heart sound, a Killip class greater than 2, a Forrester subset
f 2 or 4, dyspnea, or evidence of pulmonary congestion on chest Ta
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Table 5
8-Month clinical outcomes.
DM SES PES Non DM SES PES p value
DM vs non DM
SES vs PES
Number of lesions 149 59 356 76 – –
Binary RR, n (%) 11 (7.4) 13 (22.0), p < 0.001 23 (6.5) 12 (15.8), p < 0.001 0.159 <0.001
Number of pts 129 54 308 71 – –
TLR,  n (%) 8 (6.2) 6 (11.1), p = 0.254 19 (6.2) 8 (11.2), p = 0.278 0.822 0.061
MACE, n (%) 19 (14.7) 13 (24.0), p = 0.129 26 (8.4) 10 (14.1), p = 0.144 0.007 0.016
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pM,  diabetes mellitus; SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; b
ajor  adverse cardiac events.
adiographs [12]. The endpoint was a composite of MACE during
n 8-month follow-up interval and TLR on follow-up angiography.
tatistical analysis
Data are reported as the means ± standard deviation. Baseline,
esion, and angiographic characteristics were compared both in
iabetic versus non-diabetic patients and SES versus PES using
earson’s chi-square test, Student’s t test or a non-parametric test
Mann–Whitney method). A p-value of <0.05 was considered sta-
istically signiﬁcant. All statistical analyses were performed using a
ersonal computer with the SPSS for Windows statistical package
SPSS Inc., Chicago, IL, USA).
esults
aseline clinical, angiographic, and procedural data
A total of 562 patients with 676 lesions were treated with SES or
ES, of whom 183 patients were diabetic, and 44 patients (24.0%)
equired insulin 〈32/129 (25%) for SES and 12/54 (22.2%) for PES,
 = 0.621〉. SES was used in 70.5% (129/183) of diabetic patients and
1.3% (308/379) of non-diabetic patients. Patients with DM were
ounger (p = 0.031), had more hypertension and dyslipidemia than
hose without DM, and had a higher rate of previous myocardial
nfarction and previous PCI (p < 0.001 for each) (Table 1). There was
o difference between the two groups in left ventricular ejection
raction estimated by echocardiography.
Target lesion location and angiographic lesion characteristics at
he baseline revealed no signiﬁcant differences between the DM
nd non-DM groups and SES and PES in each group (Table 2).
Procedural and quantitative angiographic results are summa-
ized in Table 3. Although there were no signiﬁcant differences
etween diabetic and non-diabetic groups, pre-minimum luminal
iameter (MLD) (mm)  was smaller in the DM group (0.58 ± 0.34,
.68 ± 0.37, p = 0.016). Furthermore, there was a higher number of
tents, stent length and lesion length were longer, and pre-MLD
as larger in the SES group than in the PES group (Table 3).
ollow-up angiographic data
Follow-up angiography at 8 months was performed in 183
atients with 208 lesions in the DM group and 379 patients with
32 lesions in the non-DM group. Patients who did not undergo
ollow-up angiography did not differ signiﬁcantly from those who
id with respect to the baseline characteristics. Table 4 shows the
esults of quantitative analysis of follow-up angiography. There
ere no signiﬁcant differences between the DM and non-DM
roups. MLD  at 8 months was larger and late losses were smaller in
he SES group than in the PES group (Table 4). In the diabetic group,
he difference in late luminal loss between the SES group and PES
roup was 0.45 mm (0.24 ± 0.63 mm,  0.69 ± 0.68 mm,  respectively,
 < 0.001), as in the non-diabetic group (0.38 mm;  0.23 ± 0.56 mm, RR, binary restenosis rate; pts, patients; TLR, target lesion revascularization; MACE,
0.61 ± 0.63 mm,  respectively, p < 0.001). In particular, in the DM
group with restenosis, late loss was  1.11 ± 0.35 mm in the SES group
and 1.23 ± 0.89 mm in the PES group (p = 0.800) (data not shown).
Clinical outcomes
The binary restenosis rate and other clinical events at 8-months’
follow-up are summarized in Table 5. The binary restenosis rate was
signiﬁcantly lower in the SES group than in the PES group both in
the DM (7.4% vs 22.0%, p < 0.001) and non-DM groups (6.5% vs 15.8%,
p < 0.001). Furthermore, SES reduced the rate of binary restenosis
in the DM group to a similar degree as the non-DM group (8.1%,
p = 0.180). The incidence ratio of TLR to angiographic restenosis in
our study was  72.7% (8 of 11) in patients treated with SES and 46.2%
(6 of 13) in patients treated with PES in diabetic patients (Table 5).
In the DM group, there were no signiﬁcant differences between SES
and PES with respect to TLR (p = 0.254) or MACE (p = 0.129) as in the
non-DM group (p = 0.278, 0.144, respectively) (Table 5). The risk of
MACE was  signiﬁcantly higher in the DM group compared with the
non-DM group (17.5% vs 9.5%, p = 0.007) (Table 5).
Discussion
In the present study, we compared the efﬁcacy of SES and PES in
angiographic and clinical outcomes initially and at 8-month follow-
up in patients with and without DM.  In diabetic patients, SES was
associated with a lower rate of late loss, as well as a reduced risk of
binary restenosis. Nevertheless, we  found no signiﬁcant differences
in the rate of clinical outcomes, including TLR and MACE, between
the two  groups. This phenomenon was independent of the pres-
ence of diabetes. Furthermore, MACE with DES was signiﬁcantly
higher in patients with DM compared with that in patients with-
out DM.  Our results may  imply that the superiority of SES in terms
of late loss or restenosis may  not play a clinically meaningful role
in the treatment of both diabetic and non-diabetic patients in the
mid-term follow-up period. Although our results did not show any
difference in clinical event rates between SES and PES, the results
should be conﬁrmed or refuted in larger populations.
Although 3 randomized controlled trials (RCT) (ISAR-DIABETES
[13], REALITY [14], and SIRTAX [15]) involving a direct head-to-
head comparison of SES with PES in diabetic patients showed the
superiority of SES with regard to late loss and in-segment binary
restenosis, 4 RCTs including TAXi [16] showed no signiﬁcant supe-
riority of SES in TLR. Furthermore, 8 registries [9] involving a direct
head-to-head comparison of SES and PES showed no inferiority
of PES with regard to target vessel revascularization or MACE in
patients with DM.  Surprisingly, the rate of repeat intervention from
the registry data was  lower than the rate from RCT. Even though
registries [17] include more higher-risk patients than RCTs, the
actual rate of revascularization is often lower in them, whereas re-
intervention is usually symptom-driven in registries. The efﬁcacy
of two stents in patients with DM remains controversial, and there
are no data from RCTs or registries, especially in Japanese patients.
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We  assessed late loss at follow-up angiography as the angio-
raphical outcome of our study because it reﬂects the degree of
eointimal proliferation [18]. Late loss is the most sensitive mea-
ure of the antiproliferative effectiveness of DES [19]. SES has been
hown to afford a lower late loss in all trials with angiographic
ollow-up directly comparing SES and PES [13,20–22].  Although
he impact of small differences in late loss on clinical outcome
t the low end of the scale remains a source of debate, it may  be
f particular importance in diabetic patients with smaller vessels
23]. Actually, vessel size in patients with DM was  also signiﬁcantly
maller than that in patients without DM in the present study. The
otent suppression of neointimal hyperplasia associated with SES
ompared with PES resulted in lower rates of restenosis in small
essel studies [24,25].  The binary restenosis rate was  similar among
iabetic patients in ISAR-DIABETES (SES: 6.9%, PES: 16.5%), SIRTAX
SES: 7.6%, PES: 17.0%), and the present study (SES: 7.4%, PES 22.0%),
lthough a real world registry SCAAR [26] showed a lower rate (SES:
.9%, PES 5.1%).
The incidence ratio of TLR to angiographic restenosis in our
tudy was 73% in patients treated with SES and 46% in patients
reated with PES in diabetic patients. A previous randomized trial
27] showed an incidence of 85% among patients assigned to receive
ES. It is difﬁcult to be certain of the reason for this lower rate
n our study. In the present study, although late loss in the PES
roup with restenosis was larger than the SES group with resteno-
is, standard deviation was greater in the PES group. There may
ave been less late loss cases in the PES group, so in those cases,
he degree of neointimal hyperplasia was low. The present study,
owever, included protocol-mandated angiography at follow-up,
hich is likely to increase the number of TLR.
There was no difference in terms of TLR and clinical events such
s MACE between SES and PES in patients with and without DM.
ate loss of less than 0.6 mm  may  be a poor predictor of TLR [28].
ost of the previously mentioned studies reporting the superior-
ty of SES in MACE may  be because PES was frequently used in
icker patients with more complex lesions, perhaps due to the eas-
er deliverability of PES in complex coronary lesions. However, we
ound no difference in the baseline characteristics between the 2
tents, even with the higher usage rate of PES in diabetic patients.
he present study is important in that we report a patient popula-
ion with similar complexity. Kuchulakanti et al. [29] reported that
here were no signiﬁcant differences in death, MACE, or TLR with
ifferent stent types in 1320 patients with DM receiving SES or PES.
owever, the follow-up time in the study was less than 1 year, leav-
ng out long-term effects as in the present study. Although SIRTAX
15] showed that SES more effectively reduced MACE than PES dur-
ng 2-year follow-up, a recent meta-analysis [30] encompassing 35
CTs reported similar safety and efﬁcacy of the 2 types of DES in
 diabetic versus non-diabetic cohort for a longer follow-up dura-
ion. Therefore, even if we evaluate with longer term follow-up, the
esults may  be similar and it would not be clinically problematic for
 patient’s therapy with DM regardless of the stent used. Further-
ore, SES or PES can be compared equally to second-generation
ES without concerns about safety or efﬁcacy.
The risk of MACE was signiﬁcantly higher in the DM group
ompared with the non-DM group. The DM group had a higher
revalence of hypertension, hyperlipidemia, multi-vessel disease,
nd previous myocardial infarction. On the basis of these differ-
nces, more serious clinical events (MACE) in diabetic patients
ould be expected compared with non-diabetic patients. We  did not
nd any signiﬁcant inﬂuence of gender or type of antidiabetic med-
cation on MACE. This result is in agreement with a previous report
y Laham et al. [31], who found DM itself to be an independent
redictor of adverse clinical events. The hyperglycemic state itself
s of crucial importance for the excessive risk of diabetic patients
ith an enhanced thrombotic milieu or endothelial dysfunction by
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increasing oxidative stress [32]. DES has a greater beneﬁcial effect
compared to a bare metal stent or balloon angioplasty [2,5,33] in
terms of reducing clinical events in patients with DM,  but DES
could not show such a beneﬁcial effect comparing patients with
and without DM.
We  acknowledge some limitations in our study. First, the
present study was a real world, but single center, non-randomized
and retrospective study. Second, SES was less used in DM patients.
This may have affected the results, indicating SES may  have been
used less frequently than PES for tighter stenosis in the diabetic
group, so SES may  have failed to show any clinical advantage. Third,
lesion length was  longer in the SES group, which negatively affected
it. Fourth, the number of cases was  low in both groups, so lower
estimates could be inﬂuenced by chance, reducing the potential to
increase the power and improve the precision of treatment efﬁ-
cacy and safety. Further studies on a larger number of patients are
warranted.
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